Engineering the future of heart attack care

We’re building ultrasound catheters for rapid clot disruption and
microvascular protection during PCI.

Engineering the future
of heart attack care

We’re building ultrasound catheters for rapid clot disruption and microvascular protection during PCI.

When there's no solution

1 out of 3 heart attack patients still develops microvascular obstruction (MVO), blockage in the heart’s smallest blood vessels — even after timely treatment. MVO remains a major driver of poor recovery, heart failure, and long-term mortality after heart attack treatment.

Our Solution

A first-in-class dual-action catheter solution, preclinically validated and designed to enhance PCI performance through ultrafast acoustic thrombus disruption, local fragment capture, and closed-loop safety control, without lytic drugs.

Breakthrough research originating at ETH Zurich

Proprietary, patent-pending catheter technology

Compatible with existing PCI workflows

Strategic medtech partnerships and investor inquiries

SonoRobotics develops catheter-based ultrasound technology for thrombus disruption and microvascular protection in PCI workflows.

Discuss Collaboration

Years of Research

Patents & Pending patent

Engineering the future of heart attack care

We’re building ultrasound catheters for rapid clot disruption and
microvascular protection during PCI.

Engineering the future
of heart attack care

We’re building ultrasound catheters for rapid clot disruption and microvascular protection during PCI.

When there's no solution

When there's no solution

When there's no solution

1 out of 3 heart attack patients still develops microvascular obstruction (MVO), blockage in the heart’s smallest blood vessels — even after timely treatment. MVO remains a major driver of poor recovery, heart failure, and long-term mortality after heart attack treatment.

1 out of 3 heart attack patients still develops microvascular obstruction (MVO), blockage in the heart’s smallest blood vessels — even after timely treatment. MVO remains a major driver of poor recovery, heart failure, and long-term mortality after heart attack treatment.

Our Solution

Our Solution

Our Solution

Innovation supported by

Innovation supported by